Eton Pharmaceuticals (ETON) Net Margin (2019 - 2026)

Eton Pharmaceuticals has disclosed Net Margin across 8 years of filings, most recently posting 30.8% for Q2 2026.

• In Q2 2026, Net Margin rose 4446.0% year-over-year to 30.8%; the TTM figure through Jun 2026 stood at 9.52% (up 1799.0% YoY), while the FY2025 annual figure was 4.5%, up 734.0% from the prior year.
• Net Margin came in at 30.8% for Q2 2026 at Eton Pharmaceuticals, up from 11.67% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 38.0% in Q2 2023 to a low of 244.94% in Q1 2022.
• Average Net Margin over 5 years is 25.14%, with a median of 10.18% recorded in 2024.
• The largest YoY upside for Net Margin was 69173 bps in 2022 against a maximum downside of 28795 bps in 2022.
• Over 5 years, Net Margin stood at 33.02% in 2022, then slumped by 193 bps to 30.85% in 2023, then jumped by 61 bps to 11.99% in 2024, then jumped by 197 bps to 11.67% in 2025, then jumped by 164 bps to 30.8% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 30.8% in Q2 2026, 11.67% in Q4 2025, and 8.58% in Q3 2025.